CoChat
Sign Up
Cited by 16

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Probucol and cilostazol exert a combinatorial anti-atherogenic effect in cholesterol-fed rabbits

Chen, Yulong, Zhao, Sihai, Huang, Bingqiao, Wang, Yanli, Li, Yafeng, Waqar, Ahmed Bilal, Liu, Ruihan, Bai, Liang, Fan, Jianglin, Liu, Enqi·2013·Thrombosis Research
DOI 10.1016/j.thromres.2013.09.007
Open this paper in CoChat — free account

Abstract

Introduction Probucol (PB) and cilostazol (CZ) both exhibit anti-atherogenic effects. However, their combinatorial effects are unclear. This study was designed to investigate their combinatorial anti-atherogenic effect in cholesterol-fed rabbits. Materials and methods Rabbits were fed a cholesterol diet with PB or CZ alone or both PB and CZ for 16 weeks. The plasma levels of total cholesterol, LDL-cholesterol, HDL-cholesterol, C-reactive protein, superoxide dismutase, malondialdehyde, and nitric oxide (NO) were measured. The aortic atherosclerotic lesions were grossly and microscopically evaluated. Additionally, in vitro experiments were conducted using human umbilical vein endothelial cells. Results and conclusion We found that the PB group and the PB+CZ group exhibited a reduction in the lesion areas (70% in the PB+CZ group, 56% in the PB group) compared with the vehicle group. However, although PB alone and PB+CZ led to a reduction in the lesion size, the histological analysis revealed that only PB+CZ significantly decreased the macrophage accumulation and smooth muscle cell proliferation in the lesions compared with the vehicle group. The plasma levels of total cholesterol in the PB+CZ group were decreased compared with the vehicle group, Moreover, PB+CZ exerted obvious anti-oxidant and anti-inflammatory effects. Interestingly, the PB+CZ treatment led to a marked increase in the levels of plasma NO. The in vitro experiments showed that the combinatorial treatment up-regul…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.thromres.2013.09.007

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 1 references

Research works printed but not linked: 42

  1. Mathers, 2006, Projections of global mortality and burden of disease from 2002 to 2030, PLoS Med, 3, e442, 10.1371/journal.pmed.0030442 · DOI · Paper page
  2. Maron, 2000, Current perspectives on statins, Circulation, 101, 207, 10.1161/01.CIR.101.2.207 · DOI
  3. Yamashita, 2009, Where are we with probucol: a new life for an old drug?, Atherosclerosis, 207, 16, 10.1016/j.atherosclerosis.2009.04.002 · DOI
  4. Ishigami, 1997, High-density lipoproteins from probucol-treated patients have increased capacity to promote cholesterol efflux from mouse peritoneal macrophages loaded with acetylated low-density lipoproteins, Eur J Clin Invest, 27, 285, 10.1046/j.1365-2362.1997.1040657.x · DOI
  5. Lau, 2003, Probucol promotes functional reendothelialization in balloon-injured rabbit aortas, Circulation, 107, 2031, 10.1161/01.CIR.0000062682.40051.43 · DOI
  6. Hirano, 2005, Probucol enhances the expression of human hepatic scavenger receptor class B type I, possibly through a species-specific mechanism, Arterioscler Thromb Vasc Biol, 25, 2422, 10.1161/01.ATV.0000185834.98941.3d · DOI
  7. Miida, 2008, Probucol markedly reduces HDL phospholipids and elevated prebeta1-HDL without delayed conversion into alpha-migrating HDL: putative role of angiopoietin-like protein 3 in probucol-induced HDL remodeling, Atherosclerosis, 200, 329, 10.1016/j.atherosclerosis.2007.12.031 · DOI
  8. Lugnier, 2006, Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents, Pharmacol Ther, 109, 366, 10.1016/j.pharmthera.2005.07.003 · DOI
  9. Wilhite, 2003, Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time, J Vasc Surg, 38, 710, 10.1016/S0741-5214(03)01029-2 · DOI
  10. Lee, 2005, Cilostazol reduces atherosclerosis by inhibition of superoxide and tumor necrosis factor-alpha formation in low-density lipoprotein receptor-null mice fed high cholesterol, J Pharmacol Exp Ther, 313, 502, 10.1124/jpet.104.079780 · DOI
  11. Kim, 2002, Inhibition of lipopolysaccharide-induced apoptosis by cilostazol in human umbilical vein endothelial cells, J Pharmacol Exp Ther, 300, 709, 10.1124/jpet.300.2.709 · DOI
  12. Ota, 2008, Cilostazol inhibits oxidative stress-induced premature senescence via upregulation of Sirt1 in human endothelial cells, Arterioscler Thromb Vasc Biol, 28, 1634, 10.1161/ATVBAHA.108.164368 · DOI
  13. Kim, 2005, Cilostazol inhibits vascular smooth muscle cell growth by downregulation of the transcription factor E2F, Hypertension, 45, 552, 10.1161/01.HYP.0000158263.64320.eb · DOI
  14. Park, 2006, Cilostazol suppresses superoxide production and expression of adhesion molecules in human endothelial cells via mediation of cAMP-dependent protein kinase-mediated maxi-K channel activation, J Pharmacol Exp Ther, 317, 1238, 10.1124/jpet.105.098509 · DOI
  15. Nakaya, 2010, Cilostazol enhances macrophage reverse cholesterol transport in vitro and in vivo, Atherosclerosis, 213, 135, 10.1016/j.atherosclerosis.2010.07.024 · DOI
  16. Shiomi, 2005, Atheroma stabilizing effects of simvastatin due to depression of macrophages or lipid accumulation in the atheromatous plaques of coronary plaque-prone WHHL rabbits, Atherosclerosis, 178, 287, 10.1016/j.atherosclerosis.2004.10.024 · DOI
  17. Zhao, 2008, The effects of rosiglitazone on aortic atherosclerosis of cholesterol-fed rabbits, Thromb Res, 123, 281, 10.1016/j.thromres.2008.04.011 · DOI
  18. Waqar, 2010, High-fat diet without excess calories induces metabolic disorders and enhances atherosclerosis in rabbits, Atherosclerosis, 213, 148, 10.1016/j.atherosclerosis.2010.07.051 · DOI
  19. Yu, 2012, C-reactive protein levels are associated with the progression of atherosclerotic lesions in rabbits, Histol Histopathol, 27, 529
  20. Chakrabarti, 2010, 17β-Estradiol induces protein S-nitrosylation in the endothelium, Cardiovasc Res, 85, 796, 10.1093/cvr/cvp368 · DOI
  21. Forrester, 2009, Detection of protein S-nitrosylation with the biotin-switch technique, Free Radic Biol Med, 46, 119, 10.1016/j.freeradbiomed.2008.09.034 · DOI
  22. Kita, 1987, probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia, Proc Natl Acad Sci U S A, 84, 5928, 10.1073/pnas.84.16.5928 · DOI
  23. Fruebis, 1997, Effect of probucol treatment on gene expression of VCAM-1, MCP-1, and M-CSF in the aortic wall of LDL receptor-deficient rabbits during early atherogenesis, Arterioscler Thromb Vasc Biol, 17, 1289, 10.1161/01.ATV.17.7.1289 · DOI
  24. Wu, 2006, Antioxidants protect from atherosclerosis by a heme oxygenase-1 pathway that is independent of free radical scavenging, J Exp Med, 203, 1117, 10.1084/jem.20052321 · DOI
  25. Yamamoto, 2011, Pharmacologic suppression of hepatic ATP-binding cassette transporter 1 activity in mice reduces high-density lipoprotein cholesterol levels but promotes reverse cholesterol transport, Circulation, 124, 1382, 10.1161/CIRCULATIONAHA.110.009704 · DOI
  26. Bonomini, 2008, Atherosclerosis and oxidative stress, Histol Histopathol, 23, 381
  27. Niemann, 2005, Native and oxidized low-density lipoproteins stimulate endothelin-converting enzyme-1 expression in human endothelial cells, Biochem Biophys Res Commun, 334, 747, 10.1016/j.bbrc.2005.06.163 · DOI
  28. Shin, 2004, Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation: prevention by cilostazol, Circulation, 109, 1022, 10.1161/01.CIR.0000117403.64398.53 · DOI · Paper page
  29. Chang, 2005, Reduction of oxidative stress and atherosclerosis in hyperlipidemic rabbits by dioscorea rhizome, Can J Physiol Pharmacol, 83, 423, 10.1139/y05-028 · DOI
  30. Park, 2007, Beneficial synergistic effects of concurrent treatment with cilostazol and probucol against focal cerebral ischemic injury in rats, Brain Res, 1157, 112, 10.1016/j.brainres.2007.04.051 · DOI
  31. Park, 2008, Synergistic efficacy of concurrent treatment with cilostazol and probucol on the suppression of reactive oxygen species and inflammatory markers in cultured human coronary artery endothelial cells, Korean J Physiol Pharmacol, 12, 165, 10.4196/kjpp.2008.12.4.165 · DOI
  32. Bonetti, 2003, Endothelial dysfunction: a marker of atherosclerotic risk, Arterioscler Thromb Vasc Biol, 23, 168, 10.1161/01.ATV.0000051384.43104.FC · DOI
  33. Matsushita, 2003, Nitric oxide regulates exocytosis by S-nitrosylation of N-ethylmaleimide-sensitive factor, Cell, 115, 139, 10.1016/S0092-8674(03)00803-1 · DOI
  34. Lee, 2005, Nitric oxide inhibition of homocysteine-induced human endothelial cell apoptosis by down-regulation of p53-dependent Noxa expression through the formation of S-nitrosohomocysteine, J Biol Chem, 280, 5781, 10.1074/jbc.M411224200 · DOI
  35. Thibeault, 2010, S-nitrosylation of beta-catenin by eNOS-derived NO promotes VEGF-induced endothelial cell permeability, Mol Cell, 39, 468, 10.1016/j.molcel.2010.07.013 · DOI
  36. Pi, 2009, SDF-1alpha stimulates JNK3 activity via eNOS-dependent nitrosylation of MKP7 to enhance endothelial migration, Proc Natl Acad Sci U S A, 106, 5675, 10.1073/pnas.0809568106 · DOI
  37. Oliveira, 2008, The low molecular weight S-nitrosothiol, S-nitroso-N -acetylpenicillamine, promotes cell cycle progression in rabbit aortic endothelial cells, Nitric Oxide, 18, 241, 10.1016/j.niox.2008.02.001 · DOI
  38. Santhanam, 2010, Decreased S-nitrosylation of tissue transglutaminase contributes to age-related increases invascular stiffness, Circ Res, 107, 117, 10.1161/CIRCRESAHA.109.215228 · DOI
  39. Haendeler, 2004, Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: a novel vasculoprotective function of statins, Circulation, 110, 856, 10.1161/01.CIR.0000138743.09012.93 · DOI
  40. Hashimoto, 2006, Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanism, Atherosclerosis, 189, 350, 10.1016/j.atherosclerosis.2006.01.022 · DOI
  41. Jiang, 2002, Probucol preserves endothelial function by reduction of the endogenous nitric oxide synthase inhibitor level, Br J Pharmacol, 135, 1175, 10.1038/sj.bjp.0704563 · DOI
  42. Kim, 2011, Combinatorial effect of probucol and cilostazol in focal ischemic mice with hypercholesterolemia, J Pharmacol Exp Ther, 338, 451, 10.1124/jpet.111.181180 · DOI

Cited by

Sorted by citations

See all 16

Metadata

Authors
Chen, Y., Zhao, S., Huang, B., Wang, Y., Li, Y., Waqar, A. B., Liu, R., Bai, L., Fan, J., & Liu, E.
Venue
Thrombosis Research
Publisher
Elsevier BV
Published
2013-11
Volume
132
Issue
5
Pages
565-571
ISSN
0049-3848
DOI
10.1016/j.thromres.2013.09.007
Cited by
16
References
1
Language
en
Licence
Funders
  • National Natural Science Foundation of China (81070250)
  • Public Service Platform (2010FWPT-15)
  • Otsuka Pharmaceutical Co., Ltd.

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review